Most of differentially methylated CpG sites were hypomethylated in obese patients with advanced vs mild NAFLD. Methylation at FGFR2, MAT1A and CASP1 was validated in a replication cohort. This evidence concerns the gene FGFR2 and metabolic dysfunction-associated steatotic liver disease.